Does Medicare Cover a Bone Density Test for Males?

Medicare does cover bone density testing for men, but only when specific qualifying criteria are met. Unlike the blanket screening recommendation that exists for women over 65, there is no equivalent routine screening benefit for men at any age. Instead, a man needs to fall into one of several clinically defined risk categories before Medicare will pay for a DXA scan, the standard bone density test. The gap between what coverage technically allows and what actually happens in practice is striking, with research showing that eligible men are screened at a tiny fraction of the rate of eligible women.

The Qualifying Criteria for Men

Medicare’s bone density coverage traces back to the Bone Mass Measurement Act of 1997, which established specific categories of “qualified individuals.” The qualifying conditions include vertebral abnormalities suggestive of osteoporosis, long-term glucocorticoid (steroid) therapy, primary hyperparathyroidism, and monitoring the response to an approved osteoporosis drug.¹ These criteria are not sex-specific: a man on long-term prednisone or a man whose X-ray shows a suspicious compression fracture qualifies the same way a woman in those situations would.

The practical catch is that one of the most commonly used qualifying categories for women, estrogen deficiency, does not apply to men in the same way. For women, menopause itself creates a straightforward path to coverage. Men lack that automatic trigger. A man typically needs his doctor to document a specific risk factor or clinical finding, and then code the claim correctly, for Medicare to approve the test. That extra step is where a lot of men fall through the cracks.

How Often Medicare Pays for Repeat Testing

Once you qualify, Medicare reimburses a DXA scan every 24 months for preventive monitoring, or every 12 months if you are considered at elevated risk for fracture.² The 12-month interval applies, for example, to men on androgen deprivation therapy for prostate cancer or those already on osteoporosis medication whose response needs tracking.

Getting scanned more frequently than these intervals is considered low-value care, and Medicare has pushed back on it. An analysis of 2011 Medicare claims found that short-interval DXA scans, ones performed sooner than guidelines recommend, accounted for roughly one in ten of all DXA tests and cost the program about $16 million that year alone.³ For men, overuse is far less of an issue than underuse, but the frequency limits still apply to your claims.

The Screening Gap Between Men and Women

The most striking thing about bone density testing in men is not what Medicare will or will not cover but how rarely eligible men get tested at all. A study analyzing U.S. national ambulatory care survey data found that DXA ordering among men who met screening criteria was roughly 100 times less likely than among women who met screening criteria. The rate for eligible men hovered below 0.1% of qualifying visits, compared with about 5% for women, and that gap showed no significant improvement over the years studied.⁴

Even after a fracture, when the need for testing and treatment is most obvious, most men still go without. A study of over 35,000 older adults who had experienced a fracture found that only about 6% of men received osteoporosis testing or treatment within six months, compared with roughly 12% of women.⁵ Both numbers are low. The number for men is dismal.

Part of this comes down to perception. Osteoporosis is still widely thought of as a condition that primarily affects postmenopausal women, and that framing influences both patients and doctors. Men are less likely to bring it up, and physicians are less likely to assess for it. The result is a population-level gap in diagnosis that no coverage policy can fix if the test is never ordered in the first place.

Why This Matters More Than Most Men Realize

The consequences of missed screening in men are not abstract. Men who fracture a hip fare considerably worse than women who fracture a hip. A large population-based study found that age-adjusted mortality after hip fracture was significantly higher in men, with men facing about 55% greater risk of death compared to women after the same injury.⁶ A separate study put it more starkly: men were roughly twice as likely as women to die within the first year after a hip fracture, and that higher mortality persisted into the second year as well. The leading contributor to that difference was a much higher rate of fatal infections, including pneumonia and septicemia, in men after fracture.⁷

A national analysis of hip fracture patients confirmed this pattern at scale, reporting 12-month mortality of about 37% in men compared with about 26% in women. The excess mortality in men remained strongly significant even after controlling for age, fracture type, medications, and chronic conditions.⁸ In other words, it was not simply that sicker men were fracturing; something about the combination of being male and having a hip fracture carried its own independent risk.

These are not small differences. If a screening test and early treatment can prevent even a fraction of those fractures, the stakes are genuinely life-and-death for older men in a way that the public conversation around osteoporosis rarely acknowledges.

Secondary Causes That Should Prompt Testing

One reason bone density testing is especially important for men is that male osteoporosis often has an identifiable underlying cause. Secondary causes of bone loss may be found in up to 60% of men with osteoporosis, a much higher proportion than in women, where postmenopausal bone loss is the primary driver for most cases.⁹ Those secondary causes include long-term corticosteroid use, excess alcohol consumption, low testosterone from various causes, certain gastrointestinal diseases that impair calcium absorption, and medications that affect bone metabolism.

Androgen deprivation therapy for prostate cancer is one of the most well-documented triggers. A large study of men surviving at least five years after prostate cancer diagnosis found that about 19% of those who received androgen deprivation therapy had a fracture, compared with roughly 13% of those who did not receive the therapy. The risk was directly tied to the number of treatment doses received.¹⁰ Medicare does recognize this risk: men starting or receiving androgen deprivation therapy qualify for DXA screening, and the 12-month testing interval (rather than the standard 24-month interval) applies to them.²

If you are a man taking long-term steroids for asthma or autoimmune disease, receiving hormone therapy for prostate cancer, or dealing with conditions that affect nutrient absorption, you likely already qualify for Medicare-covered DXA testing. The challenge is making sure your doctor connects those dots and orders the scan.

The T-Score Puzzle for Men

Even when men do get tested, interpreting their results involves a wrinkle that many patients and some clinicians are not fully aware of. Bone density is reported as a T-score, which compares your measurement to a reference population of healthy young adults. The question that has created years of debate is: should men’s T-scores be calculated against a young male reference group, or against a young female reference group?

Major professional organizations, including the International Society for Clinical Densitometry and more recent evidence-based guidelines, have endorsed using a female reference database for T-score calculation in men.¹¹¹² The rationale is that fracture risk at a given bone density level is similar between the sexes, so using the same reference makes clinical sense for predicting who will actually break a bone.

The practical impact of this switch is real. A study of 350 men found that switching from a male to a female reference database shifted T-scores upward, causing the proportion of men classified as having normal bone mass to rise from 22% to 33%, while those classified as osteoporotic dropped from 29% to 17%. If treatment were based on a T-score threshold, the switch would have reduced the number of men eligible for medication from 46% to 32%.¹³ A consequence is that many men who fracture will have T-scores that appear “normal” by the female-reference standard, even though their bones clearly were not strong enough.¹¹

A broader population analysis found that the overall differences in treatment eligibility between male and female reference data were relatively small when all treatment criteria were considered together, not just the T-score threshold alone.¹⁴ That is because treatment decisions also factor in fracture history, age, and other clinical risk factors. Still, if you are a man reviewing your DXA report, it is worth asking your doctor which reference database was used and understanding that a “normal” T-score does not guarantee your fracture risk is actually low.

Higher Claim Denial Rates for Men

Even when a man’s doctor does order the test and the qualifying criteria are met, men face a higher rate of claim denials than women. An analysis of Medicare reimbursement data found that the proportion of initial DXA claims denied was about 9% for men, compared with about 5% for women, a roughly 1.7-fold difference.¹⁵ The study also found significant regional variation in denial rates, meaning where you live can influence whether your claim goes through.

Some of this likely reflects documentation and coding issues. Because routine age-based screening for men does not exist in Medicare the way it does for women, the claim needs to be tied to a specific qualifying diagnosis code. If the ordering physician does not attach the right ICD code, or if the claim lacks supporting documentation for the risk factor, it is more likely to be rejected. If you are a man whose DXA claim is denied, the first step is checking that the correct qualifying diagnosis appears on the claim. Common fixable errors include missing the code for long-term steroid use or failing to document the specific indication for the test.

What the Clinical Guidelines Say About Screening Men

The American College of Physicians has long recommended that clinicians periodically assess individual risk factors for osteoporosis in older men and obtain a DXA scan for men who are at increased risk and would be candidates for drug treatment if their results warranted it.¹⁶ The Endocrine Society and other professional groups have issued similar guidance. The common thread across guidelines is that universal screening of all men at a certain age is not recommended, but targeted screening based on risk is strongly recommended.

Risk factors that should prompt a conversation with your doctor include age over 70, a history of fragility fracture at any age, long-term glucocorticoid use, low body weight, significant height loss, current smoking, heavy alcohol use, and conditions or medications that cause bone loss. If any of these apply to you, you likely qualify both clinically and for Medicare coverage. The step most men miss is simply raising the topic with their physician.

Exercise and Supplements for Male Bone Health

Whether or not you end up getting a DXA scan, the evidence on what helps maintain bone density in men is worth knowing. An 18-month randomized trial in healthy older men found that a community-based exercise program combining resistance, balance, and weight-bearing activities led to meaningful gains in bone density and strength at the hip and spine. The exercise group saw roughly a 2% net gain in femoral neck bone density and a similar gain in lumbar spine trabecular bone density. Interestingly, adding extra calcium and vitamin D through fortified milk did not enhance the bone-building response in these men, who already had adequate levels of both nutrients to begin with.¹⁷

That last finding is a useful nuance. A systematic review and meta-analysis of calcium supplementation, with or without vitamin D, in healthy males did find positive effects on bone density across the body, hip, femoral neck, and spine.¹⁸ But the benefit appears to matter most for men who are deficient or borderline in their intake. If you are already getting enough calcium and vitamin D through diet or existing supplements, piling on more does not seem to add much. Exercise, on the other hand, had clear benefits regardless of nutritional status.

For men concerned about bone health, the practical hierarchy is straightforward: regular weight-bearing and resistance exercise is the single most reliably beneficial thing you can do. Ensuring adequate calcium and vitamin D intake matters, but mostly for those who are not already getting enough. And if you have any of the risk factors discussed above, asking your doctor about a DXA scan is a low-stakes conversation that Medicare will pay for, provided the right qualifying condition is documented.

When Androgen Deprivation Therapy Changes the Equation

Prostate cancer patients on androgen deprivation therapy deserve special mention because they occupy a unique position in this landscape. They face a well-documented, dose-dependent increase in fracture risk.¹⁰ They clearly qualify for Medicare-covered DXA screening. And yet studies consistently show that even this high-risk group is undertested and undertreated.

If you or someone you know is starting androgen deprivation therapy, a baseline DXA scan before or soon after treatment begins is an important step. Medicare allows the more frequent 12-month testing interval for patients at elevated fracture risk, which includes men on these therapies. Bone loss from androgen deprivation is most rapid in the first year or two of treatment, making early monitoring particularly valuable. The fracture risk difference between treated and untreated men, about 19% versus 13% over five years, is large enough that catching and addressing bone loss early can meaningfully change outcomes.¹⁰